While a comprehensive evaluation of the relevance of MET’s translational control in the context of cancer demands further exploration, it might provide insight into the apparent paradox between sporadic MET amplifications (accounting for 3–5% of cases) and the nearly ubiquitous MET overexpression observed in cancer [200,201,202,203]. The gene discussed is MET; the disease is cancer.